IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-4.16%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 09 September 2010

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on September 10, 2010, regarding events occurring on September 9, 2010. The filing addresses Item 5.02, detailing the execution of Amended and Restated Employment Agreements with three key officers: Dr. Chang Ho Ahn (Chairman and CEO), Rakesh Soni (President and COO), and Tae Heum Jeong (SVP, CFO, and Secretary).

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms and contract modifications.

Material Changes

The primary material change involves the replacement of prior employment contracts with new agreements containing the following modifications:

  • Term Extension: Automatic one-year renewal upon expiration of the initial three-year term and subsequent consecutive terms, unless terminated earlier.
  • Salary Adjustment: Annual base salary adjustments tied to the Consumer Price Index (CPI), subject to Compensation Committee review.
  • Life Insurance: Increase in company-provided life insurance coverage from two times to four times the officer's annual base salary.
  • Tax Equalization: A one-time cash payment to cover increased income tax costs resulting from change of control provisions.
  • Change of Control Provisions: For Dr. Ahn, the requirement to seek new employment following a change in control was eliminated. For Messrs. Soni and Jeong, the requirement to seek new employment remains to mitigate the company's financial obligation.

Guidance, Outlook, and Risks

The filing contains no financial guidance, market outlook, or general risk factors. The primary contingency noted is the financial obligation triggered by a change in control event, which is now structured differently for the CEO compared to the other officers. The agreements are attached as Exhibits 10.1, 10.2, and 10.3.

Investor Verification Checklist

  • Verify the exact terms of the "change of control" provisions in the attached Exhibits 10.1, 10.2, and 10.3.
  • Confirm the specific calculation methodology for the one-time tax equalization payment.
  • Review the Compensation Committee's historical approach to CPI-based salary adjustments.
  • Assess the impact of the increased life insurance coverage on the company's benefit liabilities.